WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 315297

CAS#: 220620-09-7

Description: Tigecycline is a glycylcycline antibiotic developed by Francis Tally and marketed by Wyeth under the brand name Tygacil. It was given a U.S. Food and Drug Administration (FDA) fast-track approval and was approved on June 17, 2005. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus and Acinetobacter baumannii. The New Delhi metallo-β-Lactamase multidrug-resistant Enterobacteriaceae has also shown susceptibility to tigecycline.

Chemical Structure

CAS# 220620-09-7

Theoretical Analysis

MedKoo Cat#: 315297
Name: Tigecycline
CAS#: 220620-09-7
Chemical Formula: C29H39N5O8
Exact Mass: 585.27986
Molecular Weight: 585.65
Elemental Analysis: C, 59.47; H, 6.71; N, 11.96; O, 21.86

Price and Availability

Size Price Availability Quantity
100.0mg USD 350.0 2 Weeks
200.0mg USD 450.0 2 Weeks
500.0mg USD 550.0 2 Weeks
1.0g USD 650.0 2 Weeks
2.0g USD 950.0 2 Weeks
5.0g USD 1650.0 2 Weeks
10.0g USD 2650.0 2 Weeks
20.0g USD 3650.0 2 Weeks
Click to view more sizes and prices
Bulk inquiry

Synonym: GAR936; GAR-936; GAR936; Tigecycline; trade name: TYGACL.

IUPAC/Chemical Name: (4S,4aS,5aR,12aS)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide


InChi Code: InChI=1S/C29H39N5O8/c1-28(2,3)31-11-17(35)32-15-10-16(33(4)5)13-8-12-9-14-21(34(6)7)24(38)20(27(30)41)26(40)29(14,42)25(39)18(12)23(37)19(13)22(15)36/h10,12,14,21,31,36,38-39,42H,8-9,11H2,1-7H3,(H2,30,41)(H,32,35)/t12-,14-,21-,29-/m0/s1

SMILES Code: O=C(C1=C(O)[C@@H](N(C)C)[C@@](C[C@@]2([H])C(C(C3=C(O)C(NC(CNC(C)(C)C)=O)=CC(N(C)C)=C3C2)=O)=C4O)([H])[C@@]4(O)C1=O)N

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO.

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 585.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

  1: Shen F, Han Q, Xie D, Fang M, Zeng H, Deng Y. Efficacy and safety of tigecycline for the treatment of severe infectious diseases: an updated meta-analysis of RCTs. Int J Infect Dis. 2015 Aug 15. pii: S1201-9712(15)00204-0. doi: 10.1016/j.ijid.2015.08.009. [Epub ahead of print] Review. PubMed PMID: 26283551.

2: Di Bella S, Nisii C, Petrosillo N. Is tigecycline a suitable option for Clostridium difficile infection? Evidence from the literature. Int J Antimicrob Agents. 2015 Jul;46(1):8-12. doi: 10.1016/j.ijantimicag.2015.03.012. Epub 2015 May 1. Review. PubMed PMID: 25982915.

3: De Rosa FG, Corcione S, Di Perri G, Scaglione F. Re-defining tigecycline therapy. New Microbiol. 2015 Apr;38(2):121-36. Epub 2015 Apr 21. Review. PubMed PMID: 25915055.

4: Barberán J, Salso S, Alhambra A. [Tigecycline: 10 years of history and still in full force]. Rev Esp Quimioter. 2015 Apr;28(2):61-78. Review. Spanish. PubMed PMID: 25904513.

5: Brust K, Evans A, Plemmons R. Tigecycline in treatment of multidrug-resistant Gram-negative bacillus urinary tract infections: a systematic review. J Antimicrob Chemother. 2014 Oct;69(10):2606-10. doi: 10.1093/jac/dku189. Epub 2014 May 30. Review. PubMed PMID: 24879669.

6: Falagas ME, Vardakas KZ, Tsiveriotis KP, Triarides NA, Tansarli GS. Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections. Int J Antimicrob Agents. 2014 Jul;44(1):1-7. doi: 10.1016/j.ijantimicag.2014.01.006. Epub 2014 Feb 6. Review. PubMed PMID: 24602499.

7: Moya Cordero P, Ruiz-Aragón J, Molina Linde JM, Márquez-Peláez S, Motiva Sánchez V. [Evaluation of the efficacy and safety of tigecycline for treatment of respiratory tract infections: systematic review of literature]. Rev Chilena Infectol. 2013 Dec;30(6):591-7. doi: 10.4067/S0716-10182013000600002. Review. Spanish. PubMed PMID: 24522299.

8: Cilli A. [The yield of tigecycline in the treatment of community-acquired pneumonia]. Tuberk Toraks. 2013;61(2):155-61. Review. Turkish. PubMed PMID: 23875595.

9: Stein GE, Babinchak T. Tigecycline: an update. Diagn Microbiol Infect Dis. 2013 Apr;75(4):331-6. doi: 10.1016/j.diagmicrobio.2012.12.004. Epub 2013 Jan 26. Review. PubMed PMID: 23357291.

10: Okon E, Engell C, van Manen R, Brown J. Tigecycline-related pancreatitis: a review of spontaneous adverse event reports. Pharmacotherapy. 2013 Jan;33(1):63-8. doi: 10.1002/phar.1159. Review. PubMed PMID: 23307547.

11: Sun Y, Cai Y, Liu X, Bai N, Liang B, Wang R. The emergence of clinical resistance to tigecycline. Int J Antimicrob Agents. 2013 Feb;41(2):110-6. doi: 10.1016/j.ijantimicag.2012.09.005. Epub 2012 Nov 3. Review. PubMed PMID: 23127485.

12: Marot JC, Jonckheere S, Munyentwali H, Belkhir L, Vandercam B, Yombi JC. Tigecycline-induced acute pancreatitis: about two cases and review of the literature. Acta Clin Belg. 2012 May-Jun;67(3):229-32. Review. PubMed PMID: 22897076.

13: El-Herte RI, Baban TA, Kanj SS. Recurrent refractory Clostridium difficile colitis treated successfully with rifaximin and tigecycline: a case report and review of the literature. Scand J Infect Dis. 2012 Mar;44(3):228-30. doi: 10.3109/00365548.2011.616224. Epub 2011 Nov 13. Review. PubMed PMID: 22077098.

14: Giamarellou H, Poulakou G. Pharmacokinetic and pharmacodynamic evaluation of tigecycline. Expert Opin Drug Metab Toxicol. 2011 Nov;7(11):1459-70. doi: 10.1517/17425255.2011.623126. Epub 2011 Sep 30. Review. PubMed PMID: 21958044.

15: Tasina E, Haidich AB, Kokkali S, Arvanitidou M. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis. 2011 Nov;11(11):834-44. doi: 10.1016/S1473-3099(11)70177-3. Epub 2011 Jul 23. Review. PubMed PMID: 21784708.

16: Larson KC, Belliveau PP, Spooner LM. Tigecycline for the treatment of severe Clostridium difficile infection. Ann Pharmacother. 2011 Jul;45(7-8):1005-10. doi: 10.1345/aph.1Q080. Epub 2011 Jul 5. Review. PubMed PMID: 21730279.

17: Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother. 2011 Sep;66(9):1963-71. doi: 10.1093/jac/dkr242. Epub 2011 Jun 18. Review. PubMed PMID: 21685488.

18: Curcio D. Skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus: role of tigecycline. Clin Infect Dis. 2011 Jun 15;52(12):1468-9. doi: 10.1093/cid/cir192. Epub 2011 Apr 14. Review. PubMed PMID: 21498390.

19: Cai Y, Wang R, Liang B, Bai N, Liu Y. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother. 2011 Mar;55(3):1162-72. doi: 10.1128/AAC.01402-10. Epub 2010 Dec 20. Review. PubMed PMID: 21173186; PubMed Central PMCID: PMC3067123.

20: Eckmann C, Dryden M. Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin. Eur J Med Res. 2010 Nov 30;15(12):554-63. Review. PubMed PMID: 21163730; PubMed Central PMCID: PMC3352104.